These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36871111)

  • 41. Adaptive designs for single-arm phase II trials in oncology.
    Englert S; Kieser M
    Pharm Stat; 2012; 11(3):241-9. PubMed ID: 22411839
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Using Bayesian adaptive designs to improve phase III trials: a respiratory care example.
    Ryan EG; Bruce J; Metcalfe AJ; Stallard N; Lamb SE; Viele K; Young D; Gates S
    BMC Med Res Methodol; 2019 May; 19(1):99. PubMed ID: 31088354
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimal two-stage designs for exploratory basket trials.
    Zhou H; Liu F; Wu C; Rubin EH; Giranda VL; Chen C
    Contemp Clin Trials; 2019 Oct; 85():105807. PubMed ID: 31260789
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
    Jenkins M; Stone A; Jennison C
    Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hierarchical Bayesian clustering design of multiple biomarker subgroups (HCOMBS).
    Kang D; S Coffey C; J Smith B; Yuan Y; Shi Q; Yin J
    Stat Med; 2021 May; 40(12):2893-2921. PubMed ID: 33772843
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A robust Bayesian dose-finding design for phase I/II clinical trials.
    Liu S; Johnson VE
    Biostatistics; 2016 Apr; 17(2):249-63. PubMed ID: 26486139
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Landscape of Phase II Trials in Alzheimer's Disease.
    Lee A; Shan D; Castle D; Rajji TK; Ma C
    J Alzheimers Dis; 2023; 96(2):745-757. PubMed ID: 37840500
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Bayesian adaptive phase I-II trial design for optimizing the schedule of therapeutic cancer vaccines.
    Cunanan KM; Koopmeiners JS
    Stat Med; 2017 Jan; 36(1):43-53. PubMed ID: 27545299
    [TBL] [Abstract][Full Text] [Related]  

  • 49. TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy.
    Lin R; Coleman RL; Yuan Y
    J Natl Cancer Inst; 2020 Jan; 112(1):38-45. PubMed ID: 30924863
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bayesian optimal phase II designs with dual-criterion decision making.
    Zhao Y; Li D; Liu R; Yuan Y
    Pharm Stat; 2023; 22(4):605-618. PubMed ID: 36871961
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials.
    Grayling MJ; Dimairo M; Mander AP; Jaki TF
    J Natl Cancer Inst; 2019 Dec; 111(12):1255-1262. PubMed ID: 31218346
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimal two-stage designs for single-arm phase II oncology trials with two binary endpoints.
    Kunz CU; Kieser M
    Methods Inf Med; 2011; 50(4):372-7. PubMed ID: 21057719
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Master Protocol Trial Design for Efficient and Rational Evaluation of Novel Therapeutic Oncology Devices.
    Bitterman DS; Cagney DN; Singer LL; Nguyen PL; Catalano PJ; Mak RH
    J Natl Cancer Inst; 2020 Mar; 112(3):229-237. PubMed ID: 31504680
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update.
    Tidwell RSS; Peng SA; Chen M; Liu DD; Yuan Y; Lee JJ
    Clin Trials; 2019 Dec; 16(6):645-656. PubMed ID: 31450957
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inefficiency of two-stage designs in phase II oncology clinical trials with high proportion of inevaluable patients.
    Ji L; Whangbo J; Levine JE; Alonzo TA
    Contemp Clin Trials; 2022 Sep; 120():106849. PubMed ID: 35868503
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bayesian group sequential designs for phase III emergency medicine trials: a case study using the PARAMEDIC2 trial.
    Ryan EG; Stallard N; Lall R; Ji C; Perkins GD; Gates S
    Trials; 2020 Jan; 21(1):84. PubMed ID: 31937351
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized phase II trials: a long-term investment with promising returns.
    Sharma MR; Stadler WM; Ratain MJ
    J Natl Cancer Inst; 2011 Jul; 103(14):1093-100. PubMed ID: 21709274
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II clinical trials in oncology: are we hitting the target?
    Ang MK; Tan SB; Lim WT
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.